- £593.69m
- £849.68m
- €2.55bn
- 44
- 43
- 34
- 31
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 12.16 | ||
| PEG Ratio (f) | 0.82 | ||
| EPS Growth (f) | 17.3% | ||
| Dividend Yield (f) | 0.78% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.07 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 33.52 | ||
| Price to Sales | 0.27 | ||
| EV to EBITDA | 8.75 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 10.81% | ||
| Return on Equity | 14.4% | ||
| Operating Margin | 3.03% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 1,665.28 | 1,823.85 | 1,943.15 | 2,070.67 | 2,553.06 | 2,644.43 | 2,772.09 | 12.48% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +13.56 | -15.67 | +32.91 | +13.58 | -8.15 | +21.27 | +9.8 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Uniphar PLC is an Ireland-based diversified healthcare service company. The Company is focused on improving access to pharmaco-medical products and therapies. The Company’s divisions include Commercial & Clinical, Product Access, and Supply Chain & Retail. The Commercial & Clinical division provides outsourced services, specifically sales, marketing and multichannel account management to pharmaco-medical manufacturers, and distribution and support services to medical device manufacturers. The Product Access division consists of two services, including On Demand and Exclusive Access. On Demand provides access to pharmaco-medical products and treatments. Exclusive Access provides bespoke distribution partnerships to pharmaceutical partners around key brands. The Supply Chain & Retail division provides both pre-wholesale and wholesale distribution of pharmaceutical, healthcare and animal health products to pharmacies, hospitals and veterinary surgeons in Ireland.
Directors
- Maurice Pratt NEC (65)
- Gerard Rabbette CEO
- Tim Dolphin CFO
- Aisling McCarthy GCN
- Padraic Dempsey OTH
- Jeffrey Berkowitz NID (55)
- James Gaul NID
- Elizabeth Hoctor NID
- Paul Hogan NID
- Sue Webb NID
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 7th, 1994
- Public Since
- July 17th, 2019
- No. of Employees
- 3,262
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
London Stock Exchange- Shares in Issue
- 273,015,254
- Address
- 4045 Kingswood Drive, DUBLIN, D24 VO6K
- Web
- https://www.uniphar.ie/
- Phone
- +353 14287777
- Contact
- Allan Smylie
- Auditors
- PricewaterhouseCoopers
Latest News for UPR
Upcoming Events for UPR
Uniphar PLC Annual Shareholders Meeting
Uniphar PLC Annual Shareholders Meeting
Half Year 2024 Uniphar PLC Earnings Release
Similar to UPR
Alliance Pharma
London Stock Exchange
Animalcare
London Stock Exchange
Argent BioPharma
London Stock Exchange
AstraZeneca
London Stock Exchange
Beximco Pharmaceuticals
London Stock Exchange
FAQ
As of Today at 19:23 UTC, shares in Uniphar are trading at 220.00p. This share price information is delayed by 15 minutes.
Shares in Uniphar last closed at 220.00p and the price had moved by -14.06% over the past 365 days. In terms of relative price strength the Uniphar share price has underperformed the FTSE All Share Index by -14.03% over the past year.
The overall consensus recommendation for Uniphar is Buy. You can view the full broker recommendation list by unlocking its StockReport.
The Uniphar dividend yield is 0.72% based on the trailing twelve month period.
Last year, Uniphar paid a total dividend of €0.02, and it currently has a trailing dividend yield of 0.72%.Looking ahead, the next dividend pay date is 2024-05-14.
We do not have data on when Uniphar is to next pay dividends. The historic dividend yield on Uniphar shares is currently 0.72%.
To buy shares in Uniphar you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 220.00p, shares in Uniphar had a market capitalisation of £593.69m.
Here are the trading details for Uniphar:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: UPR
Based on an overall assessment of its quality, value and momentum Uniphar is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Uniphar is 404.89p. That is 84.04% above the last closing price of 220.00p.
Analysts covering Uniphar currently have a consensus Earnings Per Share (EPS) forecast of €0.20 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Uniphar. Over the past six months, its share price has outperformed the FTSE All Share Index by +5.83%.
As of the last closing price of 220.00p, shares in Uniphar were trading -1.77% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Uniphar PE ratio based on its reported earnings over the past 12 months is 12.16. The shares last closed at 220.00p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Uniphar's management team is headed by:
- Maurice Pratt - NEC
- Gerard Rabbette - CEO
- Tim Dolphin - CFO
- Aisling McCarthy - GCN
- Padraic Dempsey - OTH
- Jeffrey Berkowitz - NID
- James Gaul - NID
- Elizabeth Hoctor - NID
- Paul Hogan - NID
- Sue Webb - NID